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Abstract
Traumatic brain injury (TBI) leads to cellular loss, destabilization of membranes, disruption of synapses and altered brain
connectivity, and increased risk of neurodegenerative disease. A significant and long-lasting decrease in phospholipids
(PLs), essential membrane constituents, has recently been reported in plasma and brain tissue, in human and experimental
TBI. We hypothesized that supporting PL synthesis post-injury could improve outcome post-TBI. We tested this hy-
pothesis using a multi-nutrient combination designed to support the biosynthesis of PLs and available for clinical use. The
multi-nutrient, Fortasyn Connect (FC), contains polyunsaturated omega-3 fatty acids, choline, uridine, vitamins,
cofactors required for PL biosynthesis, and has been shown to have significant beneficial effects in early Alzheimer’s
disease. Male C57BL/6 mice received a controlled cortical impact injury and then were fed a control diet or a diet enriched
with FC for 70 days. FC led to a significantly improved sensorimotor outcome and cognition, reduced lesion size and
oligodendrocyte loss, and it restored myelin. It reversed the loss of the synaptic protein synaptophysin and decreased
levels of the axon growth inhibitor, Nogo-A, thus creating a permissive environment. It decreased microglia activation and
the rise in ß-amyloid precursor protein and restored the depressed neurogenesis. The effects of this medical multi-nutrient
suggest that support of PL biosynthesis post-TBI, a new treatment paradigm, has significant therapeutic potential in this
neurological condition for which there is no satisfactory treatment. The multi-nutrient tested has been used in dementia
patients and is safe and well tolerated, which would enable rapid clinical exploration in TBI.
Keywords: brain phospholipids; functional improvement; medical multi-nutrient; neuroplasticity; neuroprotection; traumatic
brain injury
Introduction
Traumatic brain injury (TBI) is a leading cause of deathand disability1–3 and survivors suffer from cognitive and
psychological disorders. The deficits post-TBI result from multiple
neurochemical and metabolic events,4 leading to neuronal loss,
dendritic, axonal, and synaptic changes,5 and white matter abnor-
malities.6–8 TBI increases the risk of neurodegenerative diseases
such as Alzheimer’s disease (AD)9 and Parkinson’s disease.10
Experimental and human TBI observations report significant syn-
aptic alterations.11–15 Brain connectivity is disrupted in TBI patients
and this is related to cognitive dysfunction.16,17 Phospholipids (PLs)
are key to the structure of membranes, and TBI triggers significant
changes in PL. A decrease in brain PL, subsequent to phospholipase
activation, was reported in rat controlled cortical impact injury (CCI)
4 days post-TBI and was still detected at 35 days.18 Homayoun and
colleagues reported changes in free fatty acids, a consequence of PL
degradation, as early as 30min post-CCI.19 Changes in PL have been
reported in cerebrospinal fluid and brain tissue of TBI patients and
in mice post-CCI.20,21 Plasma lipidomics shows lower levels of
PL in chronic TBI in humans.22 This raises the question whether
PL breakdown could become a treatment target in TBI.
Membranes contain high levels of PL23,24; the ‘‘Kennedy path-
way,’’ a series of biochemical reactions that represent the main
mechanism by which mammalian cells synthesize PL, such as
phosphatidylcholine (PC) and phosphatidylethanolamine (PE), uses
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precursors such as uridine, choline, and polyunsaturated fatty acids
(PUFAs) such as the omega-3 PUFA, docosahexaenoic acid
(DHA).25,26 Lower levels of PUFA and a decreased ratio DHA/
arachidonic acid (AA) in PL were detected in brain and plasma in
mice post-CCI.21 Low plasma choline was reported in TBI patients.27
This suggests that TBI creates a need for sustained support of PL
biosynthesis, which could be addressed by providing precursors.
Studies on PL biosynthesis28,29 have led to the development of a
medical multi-nutrient, Fortasyn Connect (FC), designed to sup-
port PL formation. FC contains DHA and also the omega-3 PUFA,
eicosapentaenoic acid (EPA), and uridine monophosphate (UMP),
choline, folic acid, vitamins B12, B6, C, and E, and selenium,
required for PL biosynthesis. FC supports synaptogenesis29–31 and
improves learning and memory.30,32 FC protects against b-amyloid
toxicity,33 and the beneficial impact of FC on memory impairment
in early AD is supported by several clinical trials.34–36 Given that
TBI leads to a decrease in PL levels in brain and plasma, we
hypothesized that FC, by providing PL precursors, could have
significant beneficial effects in TBI.
The aim was to test the effect of an FC-supplemented diet in
mice with CCI injury, a model that reproduces clinically relevant
neurobehavioral changes,37 and where PL changes have been
documented over a long period post-injury.21 Microglial activation,
hippocampal neurodegeneration and myelin loss persist up to 1
year in CCI.38 CCI studies have reported protracted increases in
lesion volume39 and impairment of spatial learning and memory.40
We hypothesized that administration of FC post-TBI could im-
prove neurological outcome and counter tissue loss.
Methods
Animals
Adult 10- to 12-week-old male C57BL/6 mice, 22–27 g (Charles
River Laboratories, Harlow, UK; http://www.criver.com/files/pdfs/
rms/c57bl6/rm_rm_d_c57bl6n_mouse.aspx), were used, housed in
groups of 4 in cages provided with enrichment objects, in a 12-h
light/dark cycle, with diet and water ad libitum. Food intake and
body weight were monitored daily. All animal procedures were
carried out under a Project Licence approved by the Animal Wel-
fare and Ethical Review Body, at Queen Mary University of Lon-
don and the UK Home Office, in accord with the EU Directive
2010/63/EU.
Controlled cortical impact model
A CCI TBI model was used.41 After a 1-week acclimatization
period, mice were anesthetized using ketamine (50mg/kg) and me-
detomidine (0.5mg/kg), administered intraperitoneally (i.p.). Mice
were placed in a stereotaxic frame and amidline longitudinal incision
was performed to expose the skull. A right lateral craniotomy was
carried out using a pneumatic drill, 2.0mm behind bregma, and
2.5mm lateral to the midline. CCI injury was induced using the
following settings: a 3-mm impactor tip with a speed of 3m/s, a depth
of 2.2mm, and a dwell time of 100ms, applied using the PCI3000
Precision Cortical Impactor (Hatteras Instruments, Inc., Cary,
NC). A control group underwent craniotomy only. Post-injury, the
skull flap was placed back and the skin was sutured. Mice were
allowed to recover in an incubator (37C) until theywere fully awake
and active. Buprenorphine (0.05mg/kg), administered subcutane-
ously, was used pre-operatively for pre-emptive analgesia and post-
operatively every 12 h for 3 days post-TBI.
Dietary supplementation
Post-CCI, mice were randomized into two groups and fed with a
control diet (CCI-Control; n= 10) or with a FC multi-nutrient diet
(CCI-FC; n= 10) for 70 days (detailed composition in Table 1). The
craniotomy group were fed with control diet (craniotomy; n= 10),
and there was no craniotomy-FC group, because the emphasis of
the study was on the brain injury component. The choice of the dose
used in this study was based on a previous study carried out in our
group, in which we tested several dose levels.42 The diets were
formulated by Nutricia Research (Utrecht, The Netherlands) and
manufactured by Ssniff (Soest, Germany), stored at -20C to
prevent lipid peroxidation, and fresh diet was given daily. Diet
stability under these conditions has been confirmed by the pro-
ducers of the diet. No significant differences were observed in the
daily food intake and body weight (Supplementary Fig. 1) (see
online supplementary material at http://www.liebertpub.com) be-
tween groups.
Experimental design and behavioral testing
Testing at various days post-injury (dpi) is summarized in Fig-
ure 1. Sample size was calculated using power analysis (https://eda
.nc3rs.org.uk/eda/) for pair-wise post-hoc comparisons after anal-
ysis of variance (ANOVA), to a statistical power of 90%, with a
significance level a= 0.05 to detect a 25% and 20% relative dif-
ference in sensorimotor behavioral scoring (Modified Neurological
Severity Score; mNSS), lesion size, and histopathology (glial
responses, cell proliferation, and white matter), as experimental
primary and secondary outcomes. All the behavior (the primary
study endpoint) was assessed in ‘‘blind,’’ with the researcher un-
aware of the treatment, in accord with ARRIVE (Animal Research:
Reporting of In Vivo Experiments) guidelines.
Modified Neurological Severity Score
The mNSS was used to evaluate motor ability, balance, and
alertness, using a scoring system based on the ability to perform 10
tasks that evaluate motor ability, balance, and alertness (Supple-
mentary Fig. 2) (see online supplementary material at http://www
.liebertpub.com). During the first week, testing was performed
every other day, then once a week, until the end of experiment. A
point was given for failure to perform a task. Tissue pathology
correlates well with impairment scores and with degree of brain
edema.43,44 The first mNSS was obtained 24 h post-TBI.
Rotarod
The Rotarod test (Ugo Basile SRL, Gemonio, Italy; 3 cm in di-
ameter) was used for the evaluation of motor coordination and bal-
ance and was carried out between days 1 and 3 post-CCI. Pre-
surgery, mice were trained on the Rotarod for 3 consecutive days.
The first two trials were 60 sec each, at a speed of 3 rpm, followed by
a single trial at accelerating speed (3–20 rpm over 300 sec), with
intervals of at least 25min of rest. The rest of the training days
consisted of one trial at a constant speed of 3 rpm followed by two
accelerating trials. The latency to fall from the Rotarodwas recorded.
The average of all accelerating phase scores was considered as the
baseline (pre-injury score). Mice were tested during days 1–3 post-
injury, in three trials a day, using the accelerating mode.
CatWalk
The CatWalk is a system for a quantitative automated assess-
ment of gait. It consists of an enclosed walkway, a camera, and
recording and analysis software (Noldus/Tracksys Ltd, Notting-
ham, UK; RRID:SCR_004074). Dynamic gait parameters were
analyzed on day 2 post-CCI. Each mouse was placed individually
in the walkway, which consists of a glass plate (100· 15· 0.6 cm)
surrounded by two black Plexiglas walls, spaced 8 cm apart. The
mouse was allowed to walk freely and traverse from one side to the
other of the walkway. Two infrared beams spaced 90 cm apart were
used to detect the arrival of the mouse and control the start and end
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of data acquisition. Recordings were carried out in a dark room.
After each trial, the walkway was cleaned with 1% acetic acid for
odor neutralization. CatWalk XT 7.0 software (Noldus) was used to
analyze the data.
Morris water maze
The Morris water maze test (MWM) was used to assess memory
deficits associated with spatial learning45 between days 13 and 18
post-CCI. A 100-cm-diameter pool filled with opaque water at
23Cwas placed inside a white tent, ensuring light uniformity, with
four visible cues hung 10 cm from the pool walls and an 11-cm
diameter Plexiglas resting platform submerged 0.5 cm below the
water level. Swimming performance (e.g., path, distance, speed,
and latency) was tracked using software (ANY-maze, Smart;
Bioseb, Vitrolles, France; RRID:SCR_014289). A learning period
of 5 consecutive days (days 13–17 post-injury) and a probe trial on
day 6 (day 18 post-injury) were used. During the learning period,
each mouse was subjected to four trials a day, in the pool divided
into four virtual quadrants. The position of the platform was con-
stant throughout the training session, whereas the starting position
on each of the four training trials was changed. If a mouse did not
find the platform within 60 sec, it was guided to it. After reaching
the platform, mice were allowed to stay there for 15 sec. During the
probe trial, mice were allowed to swim for 60 sec in the absence of
the platform, and the time it took to first enter the quadrant that had
previously hosted the platform, was measured.
Novel Object Recognition
The novel object recognition (NOR) test was used to evaluate
recognition memory on day 26 post-CCI. In the habituation phase,
on days 22–25 post-injury, animals were exposed to an empty
opaque box used as an open field, for 10min. Twenty-four hours
later, in a familiarization phase, each animal was given 20min to
explore two identical objects, placed in the same open field. Four
hours later, in the second test phase, animals were exposed to two
dissimilar objects placed in the same open field: one familiar object
used in the first phase and one novel object. In the test phase,
exploration time was 10min and time spent exploring each of the
objects was measured. Performance was tracked with software
(ANY-maze, Smart; Bioseb). A recognition index (RI), that is, the
time spent investigating the novel object relative to the total object
investigation, was calculated as follows: percentage time spent with
novel object/time spent with novel and familiar objects. Mice that
Table 1. Compositions of the Experimental Diets (g/100 g)
Ingredient Control FC
Corn starch 35.57 31.31
Caseine (>85% protein) 14.00 14.00
Corn dextrine 15.50 15.50
Sucrose 10.00 10.00
Dextrose 10.00 10.00
Fiber 5.00 5.00
Mineral mix (AIN-93M-MX) 3.50 3.50
Vitamin mix (AIN-93-VX) 1.00 1.00
Choline bitartrate (41.1% choline) 0.250 0.250
l-cystine 0.180 0.180
Tert-butylhydroquinone 0.0008 0.0008
Oil blends
Soy oil 1.900 —
Coconut oil 0.900 0.100
Corn oil 2.200 0.100
DHA25 oil — 4.500
EPA28/12 — 0.300
Other additions
Pyridoxine-HCL — 0.00529
Folic acid (90%) — 0.00111
Cyanocobalamin (0.1% in mannitol) — 0.00650
Ascorbic acid (100% pure) — 0.24000
dl-a-tocopheryl acetate (500 IU/g) — 0.70500
UMP disodium (24% H2O) — 1.50000
Choline chloride (74.576%) — 0.67046
Soy lecithine (Emulpur) — 1.13205
Total phospholipids (—) (0.8717)
Phosphatidylcholine (—) (0.2264)
Phosphatidylinositol (—) (0.1585)
Phosphatidylethanolamine (—) (0.1472)
Sodium selenite (46% min) — 0.00036
Total 100.0 100.0
Fatty acid profile Control FC
C-4:0 0.000 0.000
C-6:0 0.004 0.001
C-8:0 0.064 0.007
C-10:0 0.052 0.006
C-12:0 0.395 0.046
C-14:0 0.155 0.191
C-14:1 n5 0.000 0.000
C-15:0 0.000 0.035
C-16:0 0.492 0.795
C-16:1 n7 0.004 0.251
C-17:0 0.000 0.042
C-18:0 0.136 0.222
C-18:1 n9 1.041 0.656
C-18:2 n6 2.181 0.158
C-18:3 n3 0.107 0.038
C-18:3 n6 0.000 0.006
C-18:4 n3 0.000 0.001
C-20:0 0.020 0.018
C-20:1 n9 0.010 0.097
C-20:2 n6 0.000 0.035
C-20:3 n6 0.000 0.008
C-20:4 n3 0.000 0.000
C-20:4 n6 0.000 0.092
C-20:5 n3 0.000 0.433
C-22:0 0.009 0.011
C-22:1 n9 0.000 0.012
C-22:4 n6 0.000 0.017
(continued)
Table 1. (Continued)
Fatty acid profile Control FC
C-22:5 n3 0.000 0.074
C-22:6 n3 0.000 1.117
C-24:0 0.000 0.008
C-24:1 n9 0.000 0.014
Total FA 4.771 4.771
SAT FA 1.327 1.382
MUFA 1.055 1.030
PUFA 2.288 1.979
Other FA 0.101 0.379
MCT 0.515 0.060
Tot n6 2.181 0.316
Tot n3 0.107 1.663
n6/n3 20.298 0.190
UMP, uridine monophosphate; FC, Fortasyn Connect; FA, fatty acid;
SAT FA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid; MCT, medium-chain triglyceride.
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discriminate between the old and new object should have an RI
above 50%.46
Elevated zero maze
An elevated zero maze test (EZM) was used to assess explor-
atory behavior in an anxiety-provoking environment. Anxiety is
expressed by spending more time in the enclosed quadrants. On day
45 after CCI or craniotomy, mice were individually placed in a
closed quadrant and allowed to freely explore the maze for 5min. A
camera tracked the animal, and ANY-maze software calculated the
time spent in the open quadrants, the head dips (downward move-
ment of the head toward the floor) and stretch-attenuated postures
(elongation of the body with the feet remaining in place) from the
closed arms, and the total distance travelled during the test.
Bromodeoxyuridine injections
From day 63 post-injury or craniotomy, and for 7 sequential
days, animals received i.p. injections of 5-bromo-2-deoxyuridine
(BrdU; 50mg/kg, twice a day), to assess cell proliferation.
Histology and immunohistochemistry
At day 70 post-TBI, 5 animals from each group were deeply
anesthetized with sodium pentobarbital (50mg/kg, i.p.; Sagatal;
Rhoˆne-Me´rieux, Harlow, UK) and received a transcardiac perfu-
sion with phosphate-buffered saline (PBS; 0.01M, pH 7.4), fol-
lowed by 4% paraformaldehyde in phosphate buffer (0.1M, pH 7.4,
4C). Brains were dissected out and tissue blocks were paraffin-
fixed for histology and immunohistochemistry (IHC) analyses. All
tissue staining was performed between bregma -1.28 and bregma
-2.34, where the lesion was located. All tissue analyses were car-
ried out in ‘‘blind’’ with the researcher unaware of the treatment, in
accord with ARRIVE guidelines. Sections (7-lm) were depar-
affinized and hydrated through xylene and ethanol baths. Sections
were subjected to antigen retrieval (10mMof citrate buffer, pH 6.0,
30min at 80C) and then cooled at room temperature. Tissue was
blocked with 5% normal donkey serum in 0.2% Triton X-100 in
PBS for an hour, followed by three PBS washes. The following
primary antibodies were used (overnight incubation): rat anti-BrdU
(for cell proliferation; 1:200; Acris Antibodies GmbH, Herford,
Germany; Cat# SM1667PS Lot# RRID:AB_973414); rabbit anti–
glial fibrillary acidic protein (GFAP; for astrocytes; 1:800; Dako,
Carpinteria, CA; Cat# Z0334 Lot# RRID:AB_10013382); goat
anti–ionized calcium binding adaptor molecule 1 (Iba-1; for mi-
croglia; 1:800; Wako Chemicals USA, Inc., Richmond, VA; Cat#
019-19741 Lot# RRID:AB_839504) and rabbit anti–translocator
protein (TSPO; for glial activation following central nervous sys-
tem injury and inflammation; 1:100; Abcam, Cambridge, MA; Cat#
ab109497 Lot# RRID:AB_10862345); mouse anti–adenomatous
polyposis coli (APC; for oligodendroglia; 1:50; Millipore,
Billerica, MA; Cat# OP80 Lot# RRID:AB_2057371); rabbit
anti–cleaved caspase-3 (Asp175; for apoptosis; Cell Signaling
Technology, Danvers, MA; Cat# 9661 also NYUIHC-314,
9661S, 9661L Lot# RRID:AB_2341188); and antidoublecortin
(DCX; for immature neurons; 1:100 Millipore; Cat# AB2253
RRID:AB_1586992). The secondary antibodies were Alexa 488
or Alexa 555 (Molecular Probes, Leiden, The Netherlands;
1:200), and Hoechst 33342 stain (Sigma-Aldrich, Gillingham,
UK; 1 lg/mL of PBS) was used to visualize nuclei. Slides were
mounted and cover-slipped using Vectashield fluorescent
mounting medium (H-1000; Vector Laboratories, Burlingame,
CA). A subset of representative randomly selected sections across
the whole lesion was used for Luxol fast blue (Sigma-Aldrich,
UK) myelin staining.
For calculation of lesion size, sections of 7lm, 200lm apart,
and spanning the entire rostrocaudal extent of the injured cortex
were stained with hematoxylin and eosin (H&E). Lesion size was
measured with ImageJ software (National Institutes of Health
[NIH], Bethesda, MD) and calculated using the equation: the
contralateral (nonlesioned) hemisphere size minus the injured
hemisphere size and divided by the contralateral hemisphere size.47
Results are expressed as a percentage of hemispheric tissue.
FIG. 1. Experimental design. Behavioral testing was performed for 70 days post-injury (dpi). A controlled cortical impact (CCI) or a
control craniotomy (sham injury) were induced in adult male mice. Animals were divided into three experimental groups (craniotomy-
control, CCI-Control, and CCI-FC). All mice were tested for motor and cognitive impairments on all behavioral tests. Mice were trained
for 3 consecutive days for the Rotarod test pre-injury. Throughout the study (1–70 dpi), mice were tested for mNSS every other day on
the first week and once a week thereafter, Rotarod (1–3 dpi), CatWalk (2 dpi), MWM (13–18 dpi), novel object recognition (NOR; 22–
26 dpi), and elevated zero maze (EZM; 45 dpi). A week before the end of the study mice were injected twice a day with BrdU. Mice
were monitored daily for weight and food consumption. On 70 dpi, mice underwent perfusion for immunohistochemistry (IHC) analysis
or were decapitated and brains were quickly removed and snap frozen for western blot (WB) analysis. Seventy-day plasma and
cerebellar tissue samples were used for lipid analysis. BrdU, bromodeoxyuridine; FC, Fortasyn Connect; MWM, Morris water maze;
mNSS, Modified Neurological Severity Score; TBI, traumatic brain injury.
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Image capture analysis and processing
Four sections per animal were stained, per antibody. At least 24
fields were captured perilesionally (immediate area around the le-
sion, except for DCX, which was used to assess the differences in
the contralateral hippocampus). Images were viewed at · 40 and
photographed using a Zeiss Axioskop 2 microscope (Carl Zeiss,
Jena, Germany) with a Hamamatsu camera (C4742-95; Hama-
matsu Photonics K.K., Hamamatsu City, Japan). All image cap-
ture and quantification were performed blinded. Analyses were
done using the ImageJ program and a dedicated script ( JVP Au-
toColourCellCountsRev). Fluorescent signals under different
excitation lasers were selected by thresholding and then super-
imposed on nuclei, for colocalization. A Zeiss LSM 710 confocal
microscope was used for further characterization (ZENlite soft-
ware; Zeiss, Cambridge, UK). Figures were prepared using Il-
lustrator software (Adobe Illustrator CS6; Adobe Systems, San
Jose, CA; RRID:SCR_014198). For quantification of microglia
morphology, we measured cell size with ImageJ (ImageJ 1.50i;
NIH), for a minimum of 20 cells per animal, and 5 animals per
group.
Western blot analysis
Tissue from 5 animals from each group (CCI or craniotomy) was
used. At day 70 post-TBI, animals from each group were deeply
anesthetized with sodium pentobarbital (50mg/kg, i.p.; Sagatal;
Rhoˆne-Me´rieux), and they were decapitated. Brains were removed,
and a cube of the right hemisphere around the lesion was dissected
using a brain matrix. Tissue was snap-frozen and stored at -80C.
Samples were prepared in radioimunoprecipitation assay lysis
buffer (Sigma-Aldrich) complete with Protease Inhibitor Cocktail
(Sigma-Aldrich) and sonicated, then centrifuged (10,000g, 10min,
4C), and the supernatant was taken. Protein concentrations were
determined using the Bradford assay. Equal amounts of protein
(50 lg) were mixed with NuPAGE LDS sample buffer (Thermo
Fisher Scientific, Waltham, MA) and dithiothreitol and boiled
(95C, 10min), then separated using Mini-Protean TGX Gels,
10% (Bio-Rad, Watford, UK), and electro-transferred onto poly-
vinylidene difluoride membranes (BioTrace Medical Inc, Menlo
Park, CA). Membranes were blocked in 5% nonfat dry milk in Tris-
buffered saline (TBS; pH 7.4), with 0.1% Tween-20 (TBS/Tween)
for 1 h at room temperature. The primary antibodies used were:
mouse anti–myelin basic protein (MBP; 1:1,000; myelin marker,
Abcam; Cat# ab62631 Lot# RRID:AB_956157); mouse anti–beta-
amyloid precursor protein (b-APP; 1:500; amyloid peptide marker,
Abcam; Cat# ab11132 Lot# RRID:AB_297770); rabbit anti-Nogo-
A (1:500; myelin-derived neurite growth inhibitor, Abcam; Cat#
ab62024 Lot# RRID:AB_956171); mouse anti–post-synaptic density
95 (PSD-95; 1:500; post-synaptic density protein, Merck Millipore,
Burlington, MA; Cat# MAB1596 Lot# RRID:AB_2092365); and
rabbit anti-synaptophysin (1:1000; presynaptic protein, Cell Signal-
ing Technology; Cat# 5461S Lot# RRID:AB_10698743), all diluted
in 5% bovine serum albumin solution, and membranes were incu-
bated overnight at 4C. The primary antibody was removed and the
blots were washed in Tris-buffered saline (TBS)/Tween and incu-
bated (1 h, room temperature) in horseradish-peroxidase–conjugated
secondary antibodies (1:10,000; Jackson ImmunoResearch Labs,
West Grove, PA; Cat# 323-005-021 Lot# RRID:AB_2314648). Re-
active proteins were visualized using enhanced chemilumines-
cence (VWR International, Franklin, MA). Optical density was
determined using ImageJ software (NIH, RRID:SCR_003070).
All membranes were also incubated with a mouse polyclonal
antibody for b-actin (1:4,000; Sigma-Aldrich; Cat# A5316 Lot#
RRID:AB_476743). Protein level was expressed as relative op-
tical density, that is, the optical density of the band revealed by
the primary antibody, divided by the optical density of b-actin in
the same lane.
Phospholipid fatty acid analysis
PL fatty acid content of plasma was determined as described.48
Lipids were extracted using the method of Folch and colleagues,49
with 0.01% (w/v) 2,6-di-tert-butyl-p-cresol (butylated hydro-
xytoluene) added as antioxidant. Total PLs were isolated by thin-
layer chromatography, and the PL fatty acid composition was
measured after transesterification with 14% boron trifluoride in
methanol. Fatty acids were identified by gas chromatography with a
flame ionisation detector (Agilent 7820A; Agilent Technologies,
Santa Clara, CA) using an Omegawax capillary column (15m ·
0.10mm · 0.10 lm). Identity was confirmed by retention times
compared to standards, and quantification was performed on peak
areas with ChemStation software (Agilent Technologies). Cor-
rections were made for variations in detector response, and values
of fatty acids were normalized to 100% and expressed as wt %.
PL content of the cerebellum was measured as previously de-
scribed.50 Neutral and acidic PLs were isolated from a total lipid
extract by solid-phase extraction using Isolute bonded phase
aminopropyl columns (Kinesis Health Technologies, Dublin, UK).
The neutral PL extract was separated into PC and PE by thin-layer
chromatography and the phosphate content measured. The results
were normalized to 100-mg wet tissue weight.
Statistical analysis
Statistical analyses were done out using GraphPad Prism soft-
ware (version 5; RRID:SCR_002798; GraphPad Software Inc., La
Jolla, CA). Data are expressed as mean– standard error of the mean
(SEM). Groups were compared using one- or two-way analysis of
variance (ANOVA), followed by different post-hoc tests for mul-
tiple comparisons, and significance level set at p< 0.05.
Results
Fortasyn Connect supplementation improves
sensorimotor impairment after traumatic brain injury
TBI survivors experience sensorimotor impairment, including
paresis, postural imbalance, gait disturbance,51 and disrupted startle
response.52 TBI leads to bradykinesia, abnormal sway, and im-
paired reaction time.53,54 Early balance impairment is a predictor
of worse outcome post-TBI. Sensorimotor problems improve over
time, although some deficits may persist beyond the first 1–2 years
post-trauma.51
Sensorimotor impairment was assessed with mNSS, Rotarod, and
gait analysis. All groups showed a decrease in TBI-induced im-
pairment over 70 days, but a significant improvement was observed
in CCI FC-treated animals as early as the third day post-trauma,
compared to the CCI-control diet group. This difference in mNSS
was maintained until the end (two-way ANOVA, p < 0.0001;
F(2,27) = 320.8; Fig. 2A). Craniotomy control animals showed
only a transient impairment. Tasks where impairment was the
most prolonged were the tasks related to balance, that is, the round
and triangular stick balance tasks and the 1-cm beam walk task.
Rotarod results in the 3 days post-injury revealed better per-
formance in FC-treated animals (one-way ANOVA, p< 0.0001;
F(2,26) = 42.31; Fig. 2B). Latency to fall off the Rotarod was sig-
nificantly higher in FC-supplemented animals, compared to control
CCI animals. The craniotomy-control group showed minimal co-
ordination and balance impairment.
Gait analysis at 2 dpi using the CatWalk system revealed im-
paired locomotion in CCI-control diet animals. A long print length
reflects foot dragging and less control of the foot. We also noticed
after injury a smaller print width and a smaller print area within the
left hindpaw (LH) in the control diet group, which indicated a poor
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FIG. 2. Integrated neurological function and motor assessments. mNSS (A) and Rotarod (B). (A) From 5 dpi and thereafter, CCI-FC
animals showed a significant improvement compared to the CCI-control group (two-way ANOVA, p< 0.0001; F(2,27) = 320.8; Bon-
ferroni’s post-hoc test, **p< 0.01; ***p< 0.001); the craniotomy-control group showed significant improvement from 1 dpi and nearly
no deficits after 14 dpi (***p< .001 compared to CCI-control). (B) On 1 and 3 dpi, CCI-FC and craniotomy-control mice showed marked
improvement compared to CCI-control mice (one-way ANOVA, p < 0.0001; F(2,26) = 42.31; Bonferroni’s post-hoc test, *p< 0.05;
***p < 0.001, respectively). Data are means – SEM of 10 animals/group. Cognitive performance assessments. MWM (C) and NOR (D).
(C) A significant reduction in latency to the first entry to the platform-quadrant was observed in CCI-FC and craniotomy control animals
in the probe test (one-way ANOVA, p= 0.0005; F(2,27) = 10.17; Bonferroni’s post-hoc test, **p < 0.01; ***p < 0.001, respectively)
compared to CCI-control animals. Underneath, an illustration of the track of an animal, from release into the water until it first entered
the platform quadrant. (D) A significant increase in the time spent exploring a novel object, compared to the familiar one, was observed
in both CCI-FC and craniotomy control mice compared to CCI-control mice (one-way ANOVA, p < 0.003; F(3,36) = 5.596; Bonferroni’s
post-hoc test, *p< 0.05; **p < 0.01, respectively). Results expressed as the recognition index (RI) %: the time spent investigating the
novel object relative to the total time of object investigation. Data are means –SEM of 10 animals per group. Anxiety assessment.
Elevated zero maze (EZM; E). CCI-FC and craniotomy-control mice showed limited exploration of the unfamiliar environment, shown
by i) reduced preference for open zones, as reflected in total time spent in the open zone (one-way ANOVA, p= 0.0004; F(2,12) = 16.52;
Bonferroni’s post-hoc test, ***p< 0.001) compared to CCI-control animals; ii) a lower number of head dips (one-way ANOVA,
p = 0.0001; F(2,12) = 21.92; Bonferroni’s post-hoc test, ***p< 0.001); and iii) a reduced total distance traveled during the 5-min trial
(one-way ANOVA, p= 0.0068; F(2,12) = 7.799; Bonferroni’s post-hoc test, **p < 0.01; *p< 0.05, respectively). Data are means – SEM of
10 animals/group. ANOVA, analysis of variance; CCI, controlled cortical impact; dpi, days post-injury; FC, Fortasyn Connect; MWM,
Morris water maze; mNSS, Modified Neurological Severity Score; NOR, novel object recognition; SEM, standard error of the mean.
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control of the paw placement. The FC-treated group showed a
decrease in print length for the LH compared to the control diet
group. We also assessed the stand index (SI), which measures the
speed at which the paw loses contact with the glass plate. The SI
was higher in CCI-control diet animals compared to the other
groups, emphasizing a poor support of the LH during locomotion.
The step cycle, which runs from the initial contact to the follow-
ing contact of the same paw, was longer in the CCI-control diet
group. We also noticed a slower body speed in this group compared
to CCI-FC and craniotomy-control animals. These latter two pa-
rameters may reflect a motor ‘‘clumsiness’’ that is a consequence of
the impaired relationship between the placement of paws within a
step. The measurements indicated that TBI reduced interlimb co-
ordination and the FC diet led to partial improvement (Supple-
mentary Fig. 3) (see online supplementary material at http://www
.liebertpub.com).
Fortasyn Connect FC improves spatial memory deficits
in the Morris water maze and reduces novel object
recognition impairment after traumatic brain injury
TBI leads to deficits in cognition (e.g., memory, attention, and
information-processing speed), which are TBI-severity dependent.
The temporal lobes are vulnerable in TBI, in part because of their
location in the skull. The hippocampus plays a key role in memory
processing, recognition, acquisition, and storage of the contex-
tual details and temporal order of stimuli; hippocampal atrophy is
related to injury severity.55,56 Spatial memory was assessed using
the MWM, a test used to detect impairments in hippocampal-
dependent learning andmemory.57 CCI led to a disruption of the task
acquisition, and FC-supplemented animals did not show significant
differences compared to injured animals fed the control diet (Sup-
plementary Fig. 4) (see online supplementary material at http://www
.liebertpub.com). The probe trial revealed a major impairment post-
CCI (one-way ANOVA, p= 0.0005; F(2,27)= 10.17; Fig. 2C), which
was reversed by the FC-supplemented diet.
The NOR task is another widely used model for the investigation
of memory. Observations in primates and rodents have shown the
importance of the parahippocampal regions of the temporal lobe
(perirhinal, entorhinal, and inferior temporal cortices) for visual
object recognition memory.58
In the NOR, craniotomy-control mice spent the highest pro-
portion of time with the novel object (one-way ANOVA, p= 0.003;
F(3,36) = 5.596; Fig. 2D). CCI resulted in a significant reduction in
the RI, and this reduction was partly reversed by FC.
Fortasyn Connect reverses the disrupted behaviour
in the elevated zero maze after traumatic brain injury
TBI survivors frequently present with a delayed emergence of
increased anxiety, agitation and disinhibition, and aggressive be-
havior.59 These changes in personality disrupt relationships and
hinder rehabilitation. Anxiolytic and anxiogenic factors can be
tested using the EPM, during which animals display a preference
for dark spaces. In a CCI study, it was shown that at 21 days post-
injury, mice display a reduced anxiety.60
We tested the impact of CCI in the EZM, a modification of the
EPM that eliminates the central region of the maze, thus focusing the
analysis on the behavior in the closed and open spaces.61 CCI-injured
mice fedwith control diet showed a reduced level of anxiety compared
to control-craniotomymice, resulting in an increased exploration time
in the open areas. This correlated with a lower number of head dips
from the closed arms and a higher distance traveled compared to CCI-
FC and craniotomy-control mice. Therefore, TBI led to a disinhibition
of mice, and in CCImice receiving FC, the multi-nutrient reduced this
behavioral disinhibition (one-wayANOVA; total distance, p=0.0068,
F(2,12)=7.799; head dips, p=0.0001, F(2,12)=21.92; time spent in
open arms, p=0.0004, F(2,12)=16.52; Fig. 2E).
Fortasyn Connect–supplemented animals show
a significant reduction in lesion size
TBI is associated with a reduction in brain volume, which
continues for years after the injury.62
Analysis of lesion size showed that, at 70 dpi, there was a sig-
nificant loss of tissue, with almost total loss of ipsilateral hippo-
campus. FC supplementation significantly decreased lesion size
(one-way ANOVA; p< 0.0001, F(2,33) = 382.5; Fig. 3A,B). There
was no difference in neuronal numbers (neuronal nuclei–positive
cells) perilesionally, between the three groups (not shown).
Fortasyn Connect supplementation leads
to a decrease in microglia activation and alters
the astrocyte response post-injury
Microglia are brain immune cells derived from the yolk sac,63 with
phagocytic and antigen-presenting properties,64 which exert constant
brain surveillance.65 Their activation is a hallmark of TBI66 and is
reflected in morphological changes, from a quiescent ramified mor-
phology67 to an amoeboid aspect.68 TBI leads to microglial activation,
which can be detected in humans years after injury.69 This long-lasting
response has also been described in mouse CCI.38 One of the markers
FIG. 3. Lesion size (A and B). (A) Sections stained with H&E showing differences in lesion size. (B) Graph showing a significant
reduction in lesion size in CCI-FC mice compared to CCI-control versus craniotomy-control mice, at 70 days post-TBI (one-way
ANOVA, p< 0.0001; F(2,33) = 382.5; Bonferroni’s post-hoc test, ***p< 0.001). Data are means –SEM of 5 animals/group. Data are
means – SEM of 5 animals/group. ANOVA, analysis of variance; CCI, controlled cortical impact; dpi, days post-injury; FC, Fortasyn
Connect; H&E, hematoxylin and eosin; SEM, standard error of the mean; TBI, traumatic brain injury.
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of microglia activated post-TBI is the TSPO, located in the mito-
chondrial membrane.70 Positron emission tomography imaging has
shown an increase inTSPOpost-TBI in humans71 and in rat CCI.72We
investigated themicroglial responsewith the Iba-1 andTSPOmarkers.
The percentage of Iba-1–positive cells around the lesion was higher in
the CCI-control diet group compared to FC-CCI and craniotomy
groups (one-way ANOVA, p=0.0032; F(2,11)=10.1; Fig. 4A,B). FC
led to an overall decrease in TSPO-positive cells compared to control
diet–treated CCI animals (one-way ANOVA, p<0.0001; F(2,11)=
273.7; Fig. 4A,C). Staining for TSPO and Iba-1 showed a significantly
lower number of double-stained cells in the FC-supplemented group
compared to the CCI group on control diet (one-way ANOVA,
p<0.0001; F(2,11)=77.97; Fig. 4A,D). Notable differences in glia
morphology were observed between the CCI-control diet group
FIG. 4. Neuroinflammatory response. (A) Images of DAPI, TSPO, Iba-1, and double-labeled TSPO/Iba-1 cells. Note the different
microglia morphology (activation): amoeboid versus ramified. Scale bars= 100lm. To show colocalization, we enlarged the area marked
with a rectangle. Scale bars= 100lm. Immunohistochemistry quantification, around the lesion border, of (B) %Iba-1–positive cells (one-way
ANOVA, p= 0.0032; F(2,11)= 10.1; Bonferroni’s post-hoc test, **p< 0.01), (C) %TSPO-positive cells (one-way ANOVA, p< 0.0001;
F(2,11)= 273.7; Bonferroni’s post-hoc test, ***p< 0.001), and (D) colocalized TSPO- and Iba-1–positive cells (one-way ANOVA, p< 0.0001;
F(2,11)= 77.97; Bonferroni’s post-hoc test, ***p< 0.001). (E) Microglia cell-size analysis (Mann-Whitney U test, **p= 0.0079) and corre-
sponding images, showing the differences in cell size. Insets show the clear morphological differences. Scale bars= 100lm. Data are
means–SEMof 5 animals/group. ANOVA, analysis of variance; CCI, controlled cortical impact; DAPI, 4’,6-diamidino-2-phenylindole; FC,
Fortasyn Connect; Iba-1, ionized calcium binding adaptor molecule 1; SEM, standard error of the mean; TSPO, translocator protein.
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(predominantly amoeboid), CCI-FC diet group (less amoeboid), and
craniotomy-control group (predominantly ramified). Therefore, we
conducted an additional cell-size analysis to underline morphological
differences in the two CCI groups. Microglial cell size in the CCI-
control diet group was significantly larger compared to the CCI-FC
group (Mann-Whitney U test, p=0.0079; Fig. 4E).
Astrocytes are part of the brain macroglia and are activated post-
TBI73,74; this is attributed to the traumatic impact per se, as well as
the ischaemia, disruption of the blood–brain barrier, inflammation,
and other metabolic changes post-injury. The astrogliotic reaction is
reflected in both proliferation and cell hypertrophy.75,76 These pro-
cesses can be followed using quantification of intermediate filament
proteins and by labeling the newly formed astrocytes. In vivo im-
aging shows the heterogeneity of the astrocytic response post-injury
in mice, that is, the existence of proliferative and nonproliferative
subpopulations.75 Post-injury, astrocytes can exert both damaging
and protective effects. Some astrocytes are lost in the first days post-
injury,77 whereas later on these cells are involved in the formation of
the perilesion scar.78 Ablation of proliferative astrocytes post-CCI in
mice leads to a worse outcome, suggesting that the astrocytic re-
sponse and scar limit the injury impact.79 During remodeling post-
TBI, astrocytes may help maintain neuronal excitability.80
CCI led to an increase in astrocyte staining in the perilesional
area versus craniotomy-only animals, without any differences be-
tween the control and FC-supplemented diet (one-way ANOVA,
p< 0.0001; F(2,12) = 40.37; Fig. 5A,C). Determination of the newly
FIG. 5. Astrocyte response post-injury. (A) Images of DAPI, BrdU, GFAP, and double-labeled GFAP/BrdU cells. Arrows show
colocalization. Scale bars = 100 lm. Immunohistochemistry quantification, around the lesion border, of (B) %BrdU-positive cells (one-
way ANOVA, p< 0.0001; F(2,12) = 131.5; Bonferroni’s post-hoc test, **p < 0.01; ***p < 0.001). (C) %GFAP-positive cells (one-way
ANOVA, p < 0.0001; F(2,12) = 40.37; Bonferroni’s post-hoc test, ***p< 0.0001) and (D) colocalised %GFAP- and BrdU-positive
cells (one-way ANOVA, p < 0.0001; F(2,12) = 119.4; Bonferroni’s post-hoc test, ***p < 0.0001). Data are means – SEM of 5 animals
per group. ANOVA, analysis of variance; BrdU, bromodeoxyuridine; CCI, controlled cortical impact; DAPI, 4’,6-diamidino-2-
phenylindole; FC, Fortasyn Connect; GFAP, glial fibrillary acidic protein; SEM, standard error of the mean.
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formed astrocytes, that is, cells double-labeled with BrdU and
GFAP, showed an intense proliferation at 70 dpi, which was am-
plified by FC supplementation (one-way ANOVA, p < 0.0001;
F(2,12) = 119.4; Fig. 5A,D).
Fortasyn Connect supplementation modulates
cell proliferation and neurogenesis after controlled
cortical impact
CCI leads to a robust increase in cell proliferation, which in-
volves both glial progenitors and cells in the neurogenic niche.81
The increase in the first hours post-injury is in the subventricular
zone, whereas later on an increase in BrdU-labeled cells can
be detected throughout the lesioned hemisphere, and also con-
tralaterally.82 TBI is also associated with changes in neurogen-
esis. A decreased number of immature neurons has been reported
in mouse CCI in the first week post-injury, ipsilaterally and
contralaterally.83 The assessment of the proliferating cells post-
CCI showed a significantly higher percentage of BrdU-positive
cells perilesionally compared to the craniotomy control group.
Treatment with FC led to a markedly increased cell prolifera-
tion perilesionally (one-way ANOVA, p < 0.0001; F(2,12) = 131.5;
Fig. 5A,B), and contralaterally, in the dentate gyrus (DG; one-way
ANOVA, p = 0.0098; F(2,9) = 8.069; Fig. 6A,C). In the contralat-
eral hippocampus, CCI decreased the number of immature neu-
rons (DCX-positive cells), to less than half the value detected
in craniotomy-control animals (one-way ANOVA, p = 0.0009;
F(2,6) = 27.64; Fig. 6B,D). Supplementation with FC restored the
number of immature neurons to the level observed in craniotomy-
control animals.
Fortasyn Connect supplementation leads to protection
of myelin and oligodendrocytes after traumatic
brain injury
Imaging and post-mortem studies show that altered white mater
integrity is a major consequence of TBI.84–86 Oligodendrocytes
have a key role in the white matter repair post-trauma.87 The
FIG. 6. Cell proliferation and neurogenesis. (A) Images of BrdU in the contralateral dentate gyrus (DG). Scale bars = 25lm. (C)
Immunohistochemistry quantification of BrdU-positive cells in the contralateral DG (one-way ANOVA, p = 0.0098; F(2,9) = 8.069;
Bonferroni’s post-hoc test, **p< 0.01). Data are means –SEM of 5 animals/group. Number of positive doublecortin (DCX) cells in the
contralateral DG. (B) Images of DCX in the contralateral DG. Scale bars = 25lm. (D) Quantification of DCX-positive cells in the
contralateral DG (one-way ANOVA, p= 0.0009; F(2,6) = 27.64; Bonferroni’s post-hoc test, *p < 0.05; ***p< 0.001). Data are means –
SEM of 5 animals/group. ANOVA, analysis of variance; BrdU, bromodeoxyuridine; CCI, controlled cortical impact; DAPI, 4’,6-
diamidino-2-phenylindole; FC, Fortasyn Connect; SEM, standard error of the mean.
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demyelination response post-injury in mice is already detected
3 days post-injury, with evidence of remyelination by the end of the
first week post-injury.88
Luxol fast blue staining showed myelin disruption post-CCI,
particularly in the caudate-putamen and internal capsule. Qualitative
analysis indicated preserved patterns of myelin in CCI-FC and
craniotomy-control mice (Fig. 7A), whereas CCI-control diet animals
showed severe disruption. MBP showed a statistically significant
decrease in CCI mice fed with the control diet, with the levels fully
restored after FC supplementation (one-way ANOVA, p< 0.0001;
F(2,12)=27.81; Fig. 7B). Injury reduced oligodendrocytes perile-
sionally. This CCI-induced reduction was not modified by the FC diet
(one-way ANOVA, p= 0.00417; F(2,9)= 4.619; Fig. 7C). However,
dual staining with APC and BrdU showed a much higher percentage
FIG. 7. Myelin. (A) Coronal brain sections stained with Luxol fast blue (LFB). Note differences in the internal capsule (IC), globus pallidus
(GP)-external segment, caudate-putamen (CP), and corpus callosum (CC) regions (areas marked with rectangles and enlarged). In the CCI-FC
and craniotomy control groups, myelin-stained tracts look continuous, in contrast with a dotted pattern seen in the CCI-control group, both
ipsilateral and contralateral to the injury site. (B)Myelin basic protein (MBP) levels bywestern blot.MBP20kDawas significantly increased in
the CCI-FC and craniotomy-control groups (one-wayANOVA, p< 0.0001;F(2,12)=27.81; Bonferroni’s post-hoc test, ***p< 0.001) compared
to CCI-control mice. Oligodendrocytes. (C) Quantification of oligodendrocytes (%APC-positive cells; one-way ANOVA, p= 0.0417;
F(2,9)=4.619; Bonferroni’s post-hoc test, *p< 0.05). (D) Dual-staining APC and BrdU (one-way ANOVA, p= 0.0028; F(2,9)=12.09; Bon-
ferroni’s post-hoc test, **P<0.01). (E) Dual-staining APCwith caspase-3 (one-way ANOVA, p=0.0009; F(2,9)= 16.9; Bonferroni’s post-hoc
test, *p<0.05; ***p< 0.001) and (F) images of oligodendrocytes, caspase-3, and DAPI around the lesion border. Scale bar=100lm. Data are
means–SEM of 5 animals/group. ANOVA, analysis of variance; APC, adenomatous polyposis coli; BrdU, bromodeoxyuridine; CCI,
controlled cortical impact; DAPI, 4’,6-diamidino-2-phenylindole; FC, Fortasyn Connect; SEM, standard error of the mean.
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of double-stained cells in the CCI-FC diet group compared to the
other groups (one-way ANOVA, p=0.0028; F(2,9)= 12.09; Fig. 7D).
Further, double staining of APC with caspase-3 showed a signifi-
cantly lower percentage of cells in the FC diet-CCI group compared
to the CCI-control diet group (one-way ANOVA, p=0.0009;
F(2,9)=16.9; Fig. 7E), suggesting an ongoing higher rate of apoptosis
in the untreated injured group. Overall, these findings support a
protective effect of FC onwhitematter and a significant support of the
proliferative pool of oligodendrocytes.
Fortasyn Connect modulates changes in synaptic
markers after controlled cortical impact/synaptophysin
and post-synaptic density 95
It has been shown that even mild experimental TBI, which is not
associated with development of a lesion cavity, leads to dendritic
degeneration of the apparently spared neurons in the perilesional area,
and to loss of synapses, as evidenced using synaptophysin im-
munostaining,89 as early as 3 days post-injury. Further, in the same
mild CCI mouse model, altered dendritic spine density and marked
dendritic beading and swelling were reported in the hippocampus.13
More recently, it was shown that, 24 h post-injury, dendritic spine loss
could be detected both in the ipsi- and contralateral hemisphere.90
Alterations are persistent, given that changes in the cortical dendritic
arbor have been reported at 4 months post-CCI.91 A significant de-
crease in the post-synaptic marker, PSD-95, has been reported post-
CCI, at a time when animals displayed cognitive impairment.92
The CCI group on a control diet showed a significant decrease in
synaptophysin. In contrast, in the CCI-FC group, the level of sy-
naptophysin was almost the same as that found in the craniotomy-
control group (one-wayANOVA, p< 0.0001;F(2,12)= 35.5; Fig. 8A).
We found a similar trend in the post-synaptic protein, PSD-95,
FIG. 8. Synaptic markers. Graph and cropped gels of western blot analysis of protein levels of (A) synaptophysin; 38 kDa (one-way
ANOVA, p<0.0001; F(2,12)=35.5; Bonferroni’s post-hoc test, ***p< 0.001) and (B) PSD-95; 95kDa (one-way ANOVA, p=0.4188;
F(2,12)=0.9365; Bonferroni’s post-hoc test, #p<0.06) were analyzed by western blot. Data are means–SEM of 5 animals/group. Neurite
outgrowth inhibitor and amyloid load. (C) Graph and cropped gels of western blot analysis of protein levels of Nogo-A; 180 kD (one-way
ANOVA, p=0.0002; F(2,12)=18.68; Bonferroni’s post-hoc test, ***p<0.001) and (D) b-APP; 87 kDa (one-way ANOVA, p=0.0163;
F(2,12)=5.915; Bonferroni’s post-hoc test, **p<0.01)were analyzed in both the CCI-FC and craniotomy controlmice compared toCCI-control
mice. Data are mean–SEM of 5 animals/group. b-actin was used as loading control. ANOVA, analysis of variance; b-APP, beta-amyloid
precursor protein; CCI, controlled cortical impact; FC, FortasynConnect; PSD-95, post-synaptic density 95; SEM, standard error of themean.
12 THAU-ZUCHMAN ET AL.
which was reduced post-CCI and restored after FC supplementa-
tion—however, these changes were not statistically significant
(one-way ANOVA, p= 0.4188; F(2,12) = 0.9365; Fig. 8B).
Fortasyn Connect decreases the neurite
outgrowth inhibitor and amyloid load
TBI leads to compensatory neuroplasticity, and a major impedi-
ment to recovery is the limited axonal regeneration. Factors such as the
myelin-associated inhibitor, Nogo-A, are linked to limited plasticity
post-injury. An increase in Nogo-Awas observedwithin the first week
post-injury, after rat fluid percussion injury and mouse CCI.93,94
The level of the axon growth inhibitor, Nogo-A, was upregulated
by injury and significantly reduced by the FC diet (one-way AN-
OVA, p = 0.0002; F(2,12) = 18.68; Fig. 8C).
One of the burdens associated with TBI is the increased inci-
dence of AD in TBI survivors.95 Changes in b-APP post-TBI have
been reported at both early and delayed times post-injury. An in-
crease in b-APP has been found post-CCI in rats, up to 3 days after
injury.96 We found that the tissue level of b-APP in the lesioned
area was significantly increased, and reduced by the FC diet (one-
way ANOVA, p= 0.0163; F(2,12) = 5.915; Fig. 8D).
Fortasyn Connect alters plasma phospholipid levels
of arachidonic acid, eicosapentaenoic acid,
and docosahexaenoic acid
Fatty acid composition of plasma PL at 70 dpi showed that the
FC-supplemented group had a significantly higher level of EPA and
DHA, compared to the CCI-control diet and craniotomy-control. In
contrast, a significantly lower level of AAwas found in the CCI-FC
group compared to the other two groups (two-way ANOVA,
p< 0.0001; F(2,93) = 20.45; Fig. 9a), therefore resulting in a higher
DHA/AA ratio. No changes were observed in the other fatty acids
(Supplementary Fig. 5) (see online supplementary material at
http://www.liebertpub.com). The ratio DHA/AAwas reported to be
lower at 3 months post-CCI,21 in particular in the PE fraction of
plasma PL; therefore, our results show that the FC-based inter-
vention could help improve the DHA/AA ratio post-injury.
Fortasyn Connect alters the tissue levels
of phosphatidylcholine and phosphatidylethanolamine
Analysis of PL composition in the cerebellum showed that PC
levels decreased versus craniotomy controls by 20% post-CCI, and
after FC supplementation the difference versus craniotomy controls
was reduced to 11%. PE levels decreased by 21% in the injured
animals on the control diet versus craniotomy-only, whereas after
FC supplementation the difference was only 8% (two-way ANO-
VA, p< 0.0001; F(1,26) = 47.12; Fig. 9B).
Discussion
In this study, we show, for the first time, that a specialized
medical multi-nutrient, which provides PL precursors and which
has recently been shown to reduce hippocampal atrophy in pro-
dromal AD,97 induces a significant neurological improvement and
reduces the impact of injury when administered post-TBI. The
FIG. 9. Phospholipid fatty acid composition in plasma and tissue
phospholipids. In plasma (A), a significant reduction in AA and in-
creases in EPA and DHA in CCI-FC mice compared to CCI-control
and craniotomy-control at 70 days post-TBI (one-way ANOVA,
p<0.0001; F(2,93)=20.45; Bonferroni’s post-hoc test, ***p<0.001).
Data are means – SEM of 5 animals/group. In cerebellum (B), a
reduction in tissue PC levels by 20% in injured animals on the
control diet versus craniotomy controls, reduced to 11% in the FC
supplementation group compared to craniotomy controls (one-way
ANOVA, p< 0.0001; F(2, 3)= 26.99; Bonferroni’s post-hoc test,
***p< 0.001). Data are means–SEM of 5 animals/group. PE levels
decreased by 21% in the injured animals on the control diet versus
craniotomy-only, whereas after FC supplementation the difference
versus craniotomy controls was only 8% (one-way ANOVA,
p< 0.0001; F(2, 3)= 20.82; Bonferroni’s post-hoc test, ***p< 0.001).
Data are means–SEM of 5 animals/group. AA, arachidonic acid;
ANOVA, analysis of variance; CCI, controlled cortical impact; DHA,
docosahexaenoic acid; EPA, eicosapentaenoic acid; FC, Fortasyn
Connect; PC, phosphatidylcholine; PE, phosphatidylethanolamine;
SEM, standard error of the mean; TBI, traumatic brain injury.
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intervention with FC in a murine injury model markedly improved
outcome and reduced tissue loss.
FC improved gait, balance and motor coordination, spatial and
recognition memory, and it corrected behavioral disinhibition. The
wide range of improvements throughout the period post-injury
were observed in parallel with beneficial effects on tissue.
Focal contusion TBI, such as that induced in CCI, ultimately
creates cavitation at the injury epicentre. The tissue loss is linked to
the sensorimotor and cognitive deficits.98 The lesion was decreased
after PL precursor supplementation, and lesion reduction could
be correlated with improved outcome.99 The multi-nutrient also
modified neuroinflammation. Microglia play a major role in the
inflammatory response post-TBI.100 FC reduced the activated mi-
croglia perilesionally. Activated microglia express the cholesterol
transporter protein, TSPO, and CCI led to an increase in TSPO.
Other studies have reported an increase in TSPO in models of
TBI72,101 and TBI patients.71 FC supplementation significantly
reduced TSPO expression at 70 days post-CCI.
Microglial activation may relate to white matter disruption.102
Colocalization of MBP immunoreactivity with microglia post-TBI
suggests that myelin fragments could provide a persistent trigger
for inflammation, by stimulating microglial activation.103 The in-
creased activated microglia post-TBI also correlate with elevated
tissue levels of b-amyloid (Ab).104 The reduction in activated mi-
croglia around the lesion, after FC, may have contributed to axonal
protection by lessening the accumulation of Ab. This accumulation
occurs in damaged axons post-TBI, and axonal injury can be detected
using labeling for b-APP.16,74,105,106 Our data show an increased
expression of b-APP in injured tissue, as reported previously,107,108
and supplementation with FC partially reversed this.
Astrocytes have a pivotal role post-TBI and undergo reactive
astrogliosis.80 Astrocytes control leukocyte infiltration, blood–
brain barrier repair, and neuronal degenerative processes post-TBI
and act as buffers for neurotransmitter excess and modulate neu-
rovascular coupling.109 Disruption of the links between astrocytes
and oligodendrocytes can result in demyelination, in parallel with
motor impairment.110 Astrocytes have a role in synaptic plasticity
and neural circuit reorganization, and remyelination. We show
post-CCI an increase in newly born astrocytes post-injury and this
to a greater extent in the FC group. This may contribute to tissue
repair/regeneration processes.
We also show that the PL precursor combination protects white
matter and oligodendrocytes post-TBI. We found restored levels of
MBP, a decreased level of oligodendrocyte death, and more newly
formed oligodendrocytes. There is a strong relationship between
axon and myelin integrity—the proliferation, differentiation, and
maintenance of oligodendrocytes require axon-derived signals and
there is a continuous cross-talk and mutual dependence.111
FC stimulated neurogenesis, and treatments that stimulate neu-
rogenesis, especially in the late phase post-injury, could contribute to
circuit restoration.112–115 Functional recovery also depends on axo-
nal regeneration and sprouting, which underlie the neuroplastic
changes that accompany recovery.116 We found that the sustained
supply of FC significantly reducedNogo-A, amyelin component that
inhibits axonal growth,117 thus showing that FC enables a supportive
environment for axons. These results are in agreement withWurtman
and colleagues, who showed lower levels of Nogo-A in aged rats
after supplementation with these precursors,118 and in accord with
observations on FC supplementation after spinal cord compression.20
The multi-nutrient, FC, was developed to prevent destabilization
and loss of synapses, an early feature of AD,119 and several studies
support this mechanism of action.36 In our study, the presynaptic
protein, synaptophysin, and the post-synaptic protein, PSD-95,
were used to assess synapse loss post-TBI. In the FC group, we saw
a total reversal in the decrease in synaptophysin induced by the
injury, and a similar trend was observed for PSD-95.
Taken together, the data show pleiotropic beneficial effects of
supplementation with PL precursors post-TBI. The functional im-
provement using neurological endpoints is correlated with improved
tissue aspect, ipsilaterally and also in the contralateral hemisphere
(which has an important role in recovery post-injury).116
PC andPE levelswere reduced post-CCI even at a distance from the
injury site, as reported previously,18,19 and FC reduced these losses.
The multi-nutrient used in this study provides precursors for the
formation of PLs,31 and this novel therapeutic strategy addresses
mechanistically the chronic decrease in PL detected post-TBI in
humans.22 This consequence of injury is persistent, that is, de-
tectable at 24 months post-trauma, in an impact brain injury model
in mice,120 suggesting that it is a fundamental process of destabi-
lization of membranes, observed across species. Stocchetti and
colleagues have proposed a list of key requirements for treatments
for TBI tested pre-clinically, in order to increase the chances of
successful clinical translation.121 The PL precursor combination
tested here satisfies several requirements: 1) the relevance of the
targeted mechanism (i.e., there is a reported sustained decrease of
25–35% in several PL classes post-injury after TBI; 2) the treat-
ment tested can increase brain PL levels after 4–6 weeks of sup-
plementation (as shown by Cansev and colleagues in aged rats122
and our data here); and 3) the PL precursor preparation has been
previously shown to restore brain connectivity and reduce hippo-
campal loss in patients, in early AD, as supported by clinical trials
with FC.34,123,124
TBI triggers many injury mechanisms, which should be addressed
using multi-modal treatments.125 Specialized nutrient interventions
have the benefit of addressing multi-modal mechanisms,126 and FC
is a unique concept focused on the support of membrane integrity
through provision of precursors required for PL formation. Injury in
the nervous system triggers an extensive reorganization of circuits
ipsilaterally and in the opposite hemisphere, and it could be hy-
pothesized that FC might provide support for such restorative pro-
cesses.116,127–129
Our results show that the novel concept of providing PL pre-
cursors post-injury could have therapeutic potential in TBI. Future
studies should explore in detail in several TBI models the time
window for administration and the optimum duration of interven-
tion, in order to increase the likelihood of translational success.
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